• 1. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 2. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 3. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 4. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 5. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acid esters
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Benzoic acid esters

Research Brief on Ethyl 3-Hydrazino-4-methylbenzoate Hydrochloride (CAS: 1185302-10-6) in Chemical Biology and Pharmaceutical Applications

Ethyl 3-Hydrazino-4-methylbenzoate Hydrochloride (CAS: 1185302-10-6) is a specialized chemical compound that has garnered significant attention in recent chemical biology and pharmaceutical research. This hydrazine derivative serves as a versatile intermediate in the synthesis of biologically active molecules, particularly in the development of novel therapeutic agents. Its unique structural features, including the ethyl ester and hydrazino functional groups, make it a valuable building block for constructing more complex molecular architectures with potential pharmacological activities.

Recent studies have explored the application of Ethyl 3-Hydrazino-4-methylbenzoate Hydrochloride in the synthesis of heterocyclic compounds, which are crucial scaffolds in drug discovery. The compound's reactivity allows for efficient construction of various nitrogen-containing heterocycles, including pyrazoles, triazoles, and other fused ring systems that are prevalent in FDA-approved drugs. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its utility in creating a new class of kinase inhibitors with improved selectivity profiles.

In pharmaceutical development, this compound has shown particular promise in the synthesis of potential anticancer agents. Research teams have utilized it to create novel small molecules that target specific oncogenic pathways. The hydrochloride salt form (1185302-10-6) offers advantages in terms of solubility and stability, making it more suitable for biological screening and formulation development compared to its free base counterpart.

Analytical characterization of Ethyl 3-Hydrazino-4-methylbenzoate Hydrochloride has been extensively documented, with recent advances in spectroscopic techniques providing more detailed structural insights. Nuclear magnetic resonance (NMR) studies have confirmed the compound's purity and stability under various conditions, while mass spectrometry has been employed to track its metabolic fate in biological systems. These analytical developments have facilitated its more widespread use in medicinal chemistry programs.

The safety profile and handling requirements of 1185302-10-6 have been the subject of recent investigations. While the compound is generally stable under standard laboratory conditions, studies recommend storage in cool, dry environments protected from light. Appropriate personal protective equipment is advised when handling this material, particularly due to its hydrazine moiety which may present certain toxicity concerns at higher concentrations.

Looking forward, research directions for Ethyl 3-Hydrazino-4-methylbenzoate Hydrochloride include exploring its potential in targeted drug delivery systems and as a component in PROTAC (proteolysis targeting chimera) molecules. Several pharmaceutical companies have included derivatives of this compound in their preclinical pipelines, suggesting its growing importance in drug discovery efforts. The compound's versatility and the continuous development of novel synthetic methodologies ensure its ongoing relevance in chemical biology and pharmaceutical research.

• 933690-86-9(Ethyl 3-hydrazinyl-4-methylbenzoate)
• 883864-62-8(Benzoic acid, 4-hydrazino-3-methyl-, methyl ester)
• 90556-87-9(3-Hydrazinobenzoic Acid Ethyl Ester)
• 940875-99-0(ethyl 3-hydrazinobenzoate Hydrochloride)
• 830326-24-4(Methyl 3-hydrazinyl-4-methylbenzoate)
• 1806618-90-5(Ethyl 2-hydrazinyl-4-(hydroxymethyl)benzoate)
• 90437-32-4(ethyl 2-hydrazinylbenzoate)
• 1805710-29-5(Ethyl 3-hydrazinyl-2-(hydroxymethyl)benzoate)
• 21533-63-1(2-HYDRAZINOBENZOIC ACID METHYL ESTER HYDROCHLORIDE)
• 40566-85-6(Ethyl 4-hydrazinylbenzoate hydrochloride)